platelet-rich plasma (Puerta de Hierro University Hospital)

This is an investigational autologous biologic therapy consisting of platelet-rich plasma (PRP) derived from the patient's own blood via apheresis. Developed by the Puerta de Hierro University Hospital in Madrid, Spain, it is specifically being evaluated for the treatment of vasculogenic erectile dysfunction in patients who are non-responders to PDE5 inhibitors. The therapy involves the intracavernosal injection of a standardized platelet mass (10 μL/ml). Upon injection, the platelets release a variety of growth factors and cytokines—including VEGF, PDGF, and FGF—that promote angiogenesis, mitogenesis, and tissue healing within the corpus cavernosum, aiming to restore erectile function. The PRePED trial (NCT04502875) is a Phase 2 study comparing this standardized PRP against platelet-poor plasma (PPP).

Other names

PRPautologous platelet-rich plasmaintracavernosal PRP